Soft Tissue Sarcoma Epidemiology Forecast, 2030

Soft Tissue Sarcoma Epidemiology Forecast, 2030

“DelveInsight Business Research LLP”
DelveInsight’s ‘Soft Tissue Sarcoma – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Soft Tissue Sarcoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

DelveInsight’s ‘Soft Tissue Sarcoma – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Soft Tissue Sarcoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some key facts from the report:

1. Soft Tissue Sarcoma market report covers a descriptive overview and comprehensive insight of the Soft Tissue Sarcoma Epidemiology and Soft Tissue Sarcoma market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Soft Tissue Sarcoma market report provides insights on the current and emerging therapies.
3. Soft Tissue Sarcoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Soft Tissue Sarcoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Soft Tissue Sarcoma market.

Scope of the Report

  • The Soft Tissue Sarcoma report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Soft Tissue Sarcoma Epidemiology Report and Model provide an overview of the risk factors and global trends of Soft Tissue Sarcoma in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Soft Tissue Sarcoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Soft Tissue Sarcoma
  • The report provides the segmentation of the Soft Tissue Sarcoma epidemiology

Report Highlights

  • 11-Year Forecast of Soft Tissue Sarcoma epidemiology
  • 7MM Coverage
  • Total Cases of Soft Tissue Sarcoma
  • Total Cases of Soft Tissue Sarcoma according to segmentation
  • Diagnosed cases of Soft Tissue Sarcoma

Request for sample pages: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-epidemiology-forecast

Table of contents:

1. Key Insights

2. Executive Summary of Soft-Tissue Sarcoma (STS)

3. Soft-Tissue Sarcomas (STS) Epidemiology Overview at a Glance

3.1.     Total Incident Cases of Soft-Tissue Sarcomas (STS) in 2017

3.2.     Total Incident Cases of Soft-Tissue Sarcomas (STS) in 2030

4. Soft-Tissue Sarcomas (STS): Disease Background and Overview

4.1.     Introduction

4.2.     Types of Soft-Tissue Sarcomas (STS)

4.3.     The Molecular Biology of Soft-Tissue Sarcomas (STS)

4.4.     Stages of Soft-Tissue Sarcomas (STS)

4.5.     Diagnosis of Soft-Tissue Sarcomas (STS)

4.5.1.   Medical History and Physical Exam

4.5.2.   Imaging Tests

4.5.3.   Biopsy

4.5.4.   Pathological diagnosis of soft tissue sarcomas

4.5.5.   Proposed Diagnostic Guidelines

5. Epidemiology and Patient Population

5.1.     Key Findings

5.2.     Epidem Methodology

5.3.     7MM Incident Patient Population of Soft Tissue Sarcoma (STS)

6.       Case Reports

6.1.     Neoadjuvant chemotherapy for radiation-associated soft-tissue sarcoma (RAS): A case report

6.2.     Soft-Tissue Sarcoma Masquerading as a Hematoma

6.3.     Neoadjuvant chemotherapy for primary sarcoma of the breast: a case report

7.       Country Wise-Epidemiology of Soft Tissue Sarcoma (STS)

7.1.     United States Epidemiology

7.1.1.   Assumptions and Rationale

7.1.2.   Total Incident Cases of Soft Tissue Sarcoma (STS) in the United States

7.1.3.   Type-Specific Incidence of STS in the United States

7.1.4.   Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States

7.1.5.   Total Incident Cases of STS including GIST in the United States

7.1.6.   Incidence of STS by Extremities (%) in the United States

7.2.     EU5 Epidemiology

7.2.1.   Germany

7.2.1.1.   Assumptions and Rationale

7.2.1.2.   Total Incident Cases of Soft Tissue Sarcoma (STS) in Germany

7.2.1.3.   Gender-Specific Incidence of STS in Germany

7.2.1.4.   Type-Specific Incidence of STS in Germany

7.2.1.5.   Age-Specific Incidence of STS in Germany

7.2.1.6.   Stage-Specific Incidence of STS in Germany

7.2.1.7.   Incidence of STS by Extremities (%) in Germany

7.2.2.   France

7.2.2.1.   Assumptions and Rationale

7.2.2.2.   Total Incident Cases of Soft Tissue Sarcoma (STS) in France

7.2.2.3.   Gender-Specific Incidence of STS in France

7.2.2.4.   Type-Specific Incidence of STS in France

7.2.2.5.   Age-Specific Incidence of STS in France

7.2.2.6.   Stage-Specific Diagnosed Incidence of STS in France

7.2.2.7.   Incidence of STS by Extremities (%) in France

7.2.3.   Italy

7.2.3.1.   Assumptions and Rationale

7.2.3.2.   Total Incident Cases of Soft Tissue Sarcoma (STS) in Italy

7.2.3.3.   Gender-Specific Incidence of STS in Italy

7.2.3.4.   Type-Specific Incidence of STS in Italy

7.2.3.5.   Age-Specific Incidence of STS in Italy

7.2.3.6.   Stage-Specific Diagnosed Incidence of STS in Italy

7.2.3.7.   Incident of STS by Extremities (%) in Italy

7.2.4.   Spain

7.2.4.1.   Assumptions and Rationale

7.2.4.2.   Total Incident Cases of Soft Tissue Sarcoma (STS) in Spain

7.2.4.3.   Gender-Specific Incidence of STS in Spain

7.2.4.4.   Type-Specific Incidence of STS in Spain

7.2.4.5.   Age-Specific Incidence of STS in Spain

7.2.4.6.   Stage-Specific Incidence of STS in Spain

7.2.4.7.   Incident of STS by Extremities (%) in Spain

7.2.5.   United Kingdom

7.2.5.1.   Assumptions and Rationale

7.2.5.2.   Total Incident Cases of Soft Tissue Sarcoma (STS) in the United Kingdom

7.2.5.3.   Gender-Specific Incidence of STS in the United Kingdom

7.2.5.4.   Type-Specific Incidence of STS in the United Kingdom

7.2.5.5.   Age-Specific Incidence of STS in the United Kingdom

7.2.5.6.   Stage-Specific Diagnosed Incidence of STS in the United Kingdom

7.2.5.7.   Incident of STS by Extremities (%) in the United Kingdom

7.3.     Japan Epidemiology

7.3.1.   Assumptions and Rationale

7.3.2.   Total Incident Cases of Soft Tissue Sarcoma (STS) in Japan

7.3.3.   Gender-Specific Incidence of STS in Japan

7.3.4.   Type-Specific Incidence of STS in Japan

7.3.5.   Age-Specific Incidence of STS in Japan

7.3.6.   Stage-Specific Incidence of STS in Japan

7.3.7.   Incident of STS by Extremities (%) in Japan

8.       Appendix

8.1.     Report Methodology

9.       DelveInsight Capabilities

10.    Disclaimer

11.    About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/